enGene reposted this
We are pleased to announce a $60 million private placement! https://lnkd.in/gaMy-dxr
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients' needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN
7171 Frederick Banting
St-Laurent, Quebec H4S 1Z9, CA
200 5th Ave
Waltham, Massachusetts 02451, US
enGene reposted this
We are pleased to announce a $60 million private placement! https://lnkd.in/gaMy-dxr
We are pleased to announce a $60 million private placement! https://lnkd.in/gaMy-dxr
We are thrilled to welcome Joan Connolly as our new Chief Technology Officer. Joan brings significant experience in managing the technical operations required to drive a late-stage clinical asset through to commercialization, which will be critical as we complete the pivotal arm of our LEGEND study of detalimogene in BCG-unresponsive, non-muscle invasive bladder cancer #NMIBC #BladderCancer #CancerResearch #UroOncology
Join us live via webcast at 8:00 a.m. ET as we discuss our preliminary data from the pivotal cohort in our ongoing Phase 2 LEGEND study of detalimogene in high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (#NMIBC) with carcinoma in situ (Cis)! Webcast: https://lnkd.in/grSCSX4k Press Release: https://lnkd.in/gNunJ6AD #BladderCancer #CancerResearch #UroOncology
We are thrilled to welcome Ron Cooper as enGene's new Chief Executive Officer! https://lnkd.in/gumXGCF7
Join our CEO, Jason D. Hanson, this afternoon via webcast for his presentation at the Jefferies Global Healthcare Conference. https://lnkd.in/g2DXCZgP
As #BCAM2024 draws to a close, we express our heartfelt gratitude to the patients, families, healthcare providers, researchers, and patient advocacy organizations dedicated to raising awareness and combating bladder cancer each day. At enGene, we are unwavering in our commitment to enhancing patient lives through pioneering research and the advancement of genetic medicines. #BladderCancerAwareness #enGene #mainstreaminggeneticmedicine
On Saturday, May 18th, team enGene participated in the ‘Walk to End Bladder Cancer,’ organized by the Bladder Cancer Advocacy Network. In Boston, and virtually from Montreal, we were honored to walk alongside survivors, their families and the advocacy community, united in our mission to raise awareness and vital funds for individuals living with bladder cancer. These funds play a critical role in supporting educational programs, driving research initiatives and ensuring that no one will walk alone, and we're proud to be a part of that journey. Learn how to get involved at www.BCAN.org #BCANWalk #BladderCancerAwareness #enGene #mainstreaminggeneticmedicine
Today we recognize and celebrate the patients, researchers, and healthcare professionals who participate in clinical trials. Their tireless efforts to explore new therapies, improve patient care, and advance medicine worldwide are inspiring. We are especially grateful for the patients, their families and the participating sites in the LEGEND trial. Visit https://lnkd.in/gZ_GJEwc, to learn more about the LEGEND study. #ClinicalTrialsDay2024 #enGene #mainstreaminggeneticmedicine
enGene reposted this
Incredibly excited to welcome Paul Hastings and Wouter Joustra to the enGene team!
We would like to welcome Paul Hastings and Wouter Joustra to our Board of Directors! https://lnkd.in/g9nPjvnh